LCTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lineage Cell Therapeutics Inc (LCTX) is not a strong buy for a beginner, long-term investor at this moment. While the company shows potential in its innovative therapies and has received a positive analyst rating with an increased price target, the financial performance indicates declining net income and EPS. Additionally, there are no strong proprietary trading signals or significant catalysts to suggest immediate action. A hold strategy is recommended to monitor further developments.
The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone, and moving averages indicating upward momentum (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 1.652, R2: 1.707), suggesting limited immediate upside potential.
Analyst rating upgrade with a price target increase from $3 to $
Promising pipeline with COR1 therapy targeting significant unmet medical needs.
Bullish technical indicators.
Declining net income and EPS in the latest quarter.
Lack of significant hedge fund or insider trading activity.
No recent congress trading data or influential figure involvement.
In Q4 2025, revenue increased by 130.40% YoY to $6,608,000. However, net income dropped by 126.00% YoY to $851,000, and EPS fell to 0, down 100.00% YoY. Gross margin improved slightly by 4.62% YoY to 99.
B. Riley maintains a Buy rating and raises the price target to $4, citing the company's differentiated manufacturing approach and potential to address significant patient populations.
